Stay updated on Subcutaneous vs Intravenous Atezolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous vs Intravenous Atezolizumab in NSCLC Clinical Trial page.

Latest updates to the Subcutaneous vs Intravenous Atezolizumab in NSCLC Clinical Trial page
- Check2 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2; removed the Back to Top element. No other substantive content changes.SummaryDifference0.6%
- Check9 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.6%
- Check16 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, while removing specific location terms and listed countries.SummaryDifference31%
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.3%
- Check38 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.3%
- Check46 days agoChange DetectedThe page has been updated to version v2.16.10, and the previous service alert regarding planned maintenance has been removed.SummaryDifference4%
Stay in the know with updates to Subcutaneous vs Intravenous Atezolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous vs Intravenous Atezolizumab in NSCLC Clinical Trial page.